Skip to main content

Follow us

Home

Search

the Gateway to Research in Oklahoma

  • Researchers
  • Providers
  • Patients
  • About GRO

Gateway to Research in Oklahoma


Oklahoma Shared Clinical and Translational Resources U54 GM104938

Researchers

imgResearchers

The GRO: Researcher Portal provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in Oklahoma.

Providers

imgProviders

The GRO: Provider Portal assists medical providers to identify clinical research opportunities in Oklahoma, tools for patient education, and evidence-based resources to improve patient care.

Patients

imgPatients

The GRO: Patient Portal can help patients and families to learn more about clinical and translational research and to connect with opportunities to participate in research opportunities in your communities.

Oklahoma Research Highlights

Correction: MacCuaig et al. Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery. <em>Pharmaceutics</em> 2022, <em>14</em>, 969

1 month 3 weeks ago
Error in Figure [...].
William M MacCuaig

Scientist's Opinion on Climate Change and Hard Ticks (Ixodidae)

1 month 3 weeks ago
Tick-borne diseases account for a substantial proportion of the global incidence of infectious diseases, and their recent expansion has been increasingly associated with climate change. Nevertheless, previous studies have produced heterogeneous and often inconclusive results, largely due to differences in spatial scale, variable selection, and limited integration of climatic, ecological, and host-related drivers. Here, we assess the modeled impact of climate trends on the global distribution...
Agustín Estrada-Peña

Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism

1 month 3 weeks ago
Cancer-associated venous thromboembolism (CA-VTE) is a significant complication in oncology, contributing to morbidity, mortality, and increased healthcare utilization. Due to multiple patient- and disease-related factors, patients with cancer are at a markedly elevated risk for VTE, particularly within the first 6 months of diagnosis. The aim of this review is to provide an overview of current challenges and unmet needs in CA-VTE prediction, prevention and management. While the Khorana score...
Sanober Nusrat

Homoharringtonine and Gilteritinib Synergistically Induce Apoptosis and Suppress Viability in FLT3-ITD-Positive AML Cells

1 month 3 weeks ago
Background: The FLT3-ITD mutation is associated with a poor prognosis in acute myeloid leukemia (AML), particularly in relapsed or refractory (R/R) cases. Although Gilteritinib has been approved for the treatment of R/R AML with FLT3-ITD mutation, the emergence of resistance in clinical settings remains a major challenge. Homoharringtonine (HHT), a plant-derived alkaloid with antitumor properties, has also been used in AML treatment. However, the combination effects of HHT and gilteritinib have...
Liuting Yu

Induced Tumor-Suppressing (iTS) Cell-Based Approach for Protecting the Bone from Advanced Prostate Cancer

1 month 3 weeks ago
Advanced prostate cancer frequently metastasizes to bone, but no effective therapy exists. To seek a novel treatment option and identify a new drug target, we took an induced tumor-suppressing (iTS) cell-based approach and produced tumor-suppressing proteins and conditioned medium (CM). Notably, the overexpression of Lrp5 and β-catenin, as well as the pharmacological Wnt activator, converted osteocytes, Murine mesenchymal stem cells, mononuclear cells, and monocytes into iTS cells. While Lrp5...
Shengzhi Liu

Pagination

  • Previous page ‹ Previous
  • Page 110
  • Next page Next ›
Subscribe to

octsi logo

1000 N. Lincoln Blvd, Suite 2100, Oklahoma City, OK 73104
Copyright © 2021 The Board of Regents of the University of Oklahoma, All Rights Reserved.

About GRO

News
Publications
FAQ

Terms of Use

Privacy Policy
Accessibility

Contact

info email
info phone
Copyright © 2026. All rights reserved. Designed By Zymphonies